The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 14, 2025

Filed:

Mar. 23, 2023
Applicant:

Synthekine, Inc., Menlo Park, CA (US);

Inventors:

Paul-Joseph Penaflor-Aspuria, Redwood City, CA (US);

Scott Alan Mccauley, Menlo Park, CA (US);

Martin Oft, Palo Alto, CA (US);

Steve Kauder, Menlo Park, CA (US);

Assignee:

Synthekine, Inc., Menlo Park, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/85 (2006.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 14/55 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
A61K 38/2013 (2013.01); A61K 39/3955 (2013.01); A61K 39/4611 (2023.05); A61K 39/464 (2023.05); C07K 14/55 (2013.01); C12N 5/0636 (2013.01); C12N 15/85 (2013.01);
Abstract

The present disclosure relates to hIL2 orthogonal ligands ('IL2 orthologs') that specifically and selectively bind to the extracellular domain (ECD) a transmembrane polypeptide comprising of a modified hCD122 polypeptide. The binding of the hIL2 ortholog to the modified hCD122 polypeptide participates in the transduction pathway of intracellular signaling resulting in a biological activity of the native intracellular signaling patterns associated with hIL2 binding to either the intermediate or high affinity hIL2 receptor but which exhibits selectivity to an engineered cell expressing an hCD122 orthogonal receptor. The hIL2 orthologs of the present invention exhibit significantly reduced binding relative to their binding to the extracellular domain of wild type hCD122, either alone or when hCD122 is present in the form of an endogenous high or intermediate affinity hIL2 receptors.


Find Patent Forward Citations

Loading…